Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.
Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been identified in gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel enzymatic property of producing 2-hydroxyglutarate (2HG) from α-ketoglutarate. Here we report that 2HG-producing IDH mutants can prevent the histone demethylation that is required for lineage-specific progenitor cells to differentiate into terminally differentiated cells. In tumour samples from glioma patients, IDH mutations were associated with a distinct gene expression profile enriched for genes expressed in neural progenitor cells, and this was associated with increased histone methylation. To test whether the ability of IDH mutants to promote histone methylation contributes to a block in cell differentiation in non-transformed cells, we tested the effect of neomorphic IDH mutants on adipocyte differentiation in vitro. Introduction of either mutant IDH or cell-permeable 2HG was associated with repression of the inducible expression of lineage-specific differentiation genes and a block to differentiation. This correlated with a significant increase in repressive histone methylation marks without observable changes in promoter DNA methylation. Gliomas were found to have elevated levels of similar histone repressive marks. Stable transfection of a 2HG-producing mutant IDH into immortalized astrocytes resulted in progressive accumulation of histone methylation. Of the marks examined, increased H3K9 methylation reproducibly preceded a rise in DNA methylation as cells were passaged in culture. Furthermore, we found that the 2HG-inhibitable H3K9 demethylase KDM4C was induced during adipocyte differentiation, and that RNA-interference suppression of KDM4C was sufficient to block differentiation. Together these data demonstrate that 2HG can inhibit histone demethylation and that inhibition of histone demethylation can be sufficient to block the differentiation of non-transformed cells.
异柠檬酸脱氢酶 1(IDH1)和 IDH2 的反复突变已在神经胶质瘤、急性髓性白血病(AML)和软骨肉瘤中被鉴定出来,它们具有从α-酮戊二酸产生 2-羟基戊二酸(2HG)的新型酶促特性。在这里,我们报告产生 2HG 的 IDH 突变体可以阻止组蛋白去甲基化,而组蛋白去甲基化是谱系特异性祖细胞分化为终末分化细胞所必需的。在来自胶质瘤患者的肿瘤样本中,IDH 突变与富含神经祖细胞表达基因的独特基因表达谱相关,这与组蛋白甲基化增加有关。为了测试 IDH 突变体促进组蛋白甲基化的能力是否有助于非转化细胞中细胞分化的阻滞,我们在体外测试了新形成的 IDH 突变体对脂肪细胞分化的影响。引入突变型 IDH 或可渗透细胞的 2HG 与谱系特异性分化基因的诱导表达受到抑制和分化受阻有关。这与抑制性组蛋白甲基化标记的显著增加相关,而启动子 DNA 甲基化没有可观察到的变化。发现胶质瘤具有类似的组蛋白抑制性标记物的升高水平。将产生 2HG 的突变型 IDH 稳定转染到永生化星形胶质细胞中,导致组蛋白甲基化的逐渐积累。在所检查的标记物中,随着细胞在培养中传代,H3K9 甲基化的增加可重现性地先于 DNA 甲基化的升高。此外,我们发现 2HG 抑制性 H3K9 去甲基酶 KDM4C 在脂肪细胞分化过程中被诱导,并且 RNA 干扰抑制 KDM4C 足以阻止分化。这些数据共同表明 2HG 可以抑制组蛋白去甲基化,并且抑制组蛋白去甲基化足以阻止非转化细胞的分化。